# Enliven Therapeutics Stock Move & Outlook

Page: https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/enliven-therapeutics-stock-move-outlook
Text version: https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/enliven-therapeutics-stock-move-outlook.md
Podcast: [Business News Today | 2 Min News | The Daily News Now!](https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192)
Published: 2026-06-27T16:37:29+00:00
Episode link: https://api.fastcast.ai/audio/a96d27e9-5f35-457d-a4fe-0bbd95878848.mp3
Audio file: https://api.fastcast.ai/audio/a96d27e9-5f35-457d-a4fe-0bbd95878848.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/business-finance-news-today-2-min-news-the-daily-news-now-7726192/episodes/enliven-therapeutics-stock-move-outlook
Duration seconds: 119

## Resource

Orbimed Advisors cashed out nearly $39 million by selling 860,000 shares of Enliven Therapeutics, still holding over 6.5 million shares — a move that didn’t hurt the stock, which jumped to $50 after the sale. With a 130% one-year surge, Enliven continues its promising path in cancer drug development, advancing key candidates in early trials for chronic myeloid leukemia and HER2-mutant cancers. Positive clinical data and a strong cash reserve from a recent IPO keep investors optimistic, suggesting Orbimed’s exit may signal confidence in Enliven’s long-term potential. Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: advertise@thednn.ai This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai. View sources & latest updates: https://sources.thednn.ai/7f6898c447d95db6

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/business-finance-news-today-2-min-news-the-daily-news-now-7726192/episodes/enliven-therapeutics-stock-move-outlook/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/enliven-therapeutics-stock-move-outlook.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.